Key facts
- This page summarizes Jack W. Schuler's Form 4 filing for Accelerate Diagnostics, Inc (AXDX).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 22 Nov 2021, 15:37.
Jack W. Schuler - 18 Nov 2021 Form 4 Insider Report for Accelerate Diagnostics, Inc (AXDX)
- Reporting relationship
- Director, 10%+ Owner
- Issuer ticker
- AXDX
- Reported as of
- 18 Nov 2021
- Net transaction value
- +$605,509
- SEC form
- 4
- Accepted by SEC
- 22 Nov 2021, 15:37:32 UTC
- Prior SEC filing
- 19 Nov 2021
- Next SEC filing
- 23 Nov 2021
- Source filing
- View source filing
- Reporting owner signature
- /s/ Steven Reichling, attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Filing notes and source
Key filing fact
Jack W. Schuler filed Form 4 for Accelerate Diagnostics, Inc (AXDX) on 22 Nov 2021.
Change
- Previous filing in this sequence was filed on 19 Nov 2021.
- Current net transaction value: +$605,509.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
AXDX
transaction
Common Stock
Purchase
- Transaction value
- $605,509
- Shares
- +116,444
- Change %
- +0.68%
- Price
- $5.20
- Shares after
- 17,179,076
- Date
- 18 Nov 2021
- Ownership
- By Jack W. Schuler Living Trust
- Footnotes
- F1, F2
AXDX
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 54,975
- Date
- 18 Nov 2021
- Ownership
- By Spouse
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.15 to $5.25, inclusive. The reporting person undertakes to provide to Accelerate Diagnostics, Inc. (the "Issuer"), any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) to this Form 4.
Footnote F2
The reporting person has sole voting and dispositive power with respect to such shares in his capacity as trustee of the Jack W. Schuler Living Trust.
Footnote F3
The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.